Paul Schroy, MD, MPH
Boston Universtiy School of Medicine
Family History & Early Onset Strategic Priority Team Chair
Dr. Paul C. Schroy is Emeritus Professor of Medicine at Boston University School of Medicine with expertise in the area of colorectal cancer screening and surveillance. He has over 150 publications, and received research funding from NCI, AHRQ, CDC and ACS. Dr. Schroy’s most recent research activities have focused primarily on the development, implementation and evaluation of model programs for community-based colorectal cancer control, including: (1) exploring the role of shared decision-making as a strategy for increasing patient participation in colorectal cancer screening; (2) better defining the epidemiology of colorectal neoplasia and the development of risk assessment tools for predicting the presence of advanced neoplasia at screening colonoscopy; (3) evaluating the feasibility and validity of novel colorectal cancer screening strategies such as stool-based DNA testing and virtual colonoscopy; (4) implementation of quality measures related to colorectal cancer screening; and (5) developing strategies to reduce the public health burden of early-onset colorectal cancer.
In addition to his commitment to patient care and clinical research, Dr. Schroy is a founding member and former chair of the Massachusetts Colorectal Cancer Working Group and a founding member of the National Colorectal Cancer Roundtable. He has served in numerous leadership positions for the Roundtable, including current co-chair of the Family History and Early Onset Colorectal Cancer Task Group, former member of the Steering Committee, former co-chair of the Public Education Task Group, former co-chair of the Screening 65+ Task Group, and former chair of the Nomination Committee. He is also a former member of the Steering Committee of the Massachusetts Comprehensive Cancer Prevention and Control Network, the American Cancer Society’s New England Division’s Colorectal Cancer Advisory Committee and the Massachusetts Department of Public Health’s Cancer Registry Advisory Committee.